Bristol Myers’ TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Bristol Myers Squibb’s bet on TYK2 continued to pay off Monday, as Sotyktu passed two more Phase 3 tests in psoriatic arthritis, the company announced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Cigna, Humana in talks to merge into health insurance giant, per report

Cigna and Humana are in discussions to merge, a potential move that would create a health insurance and prescription drug benefits titan with approximately $300

November 29, 2023

Risk Adjusted Net Present Value: What is the current valuation of Soleno Therapeutics’s Diazoxide choline CR

The revenue for Diazoxide choline CR is expected to reach an annual total of $729 mn by 2034 in the US based off GlobalDatas Expiry

September 8, 2024

Bayer announces recall of cancer therapy Vitrakvi in US

Share this article Bayer is issuing the product recall with the US Food and Drug Administration’s knowledge. Credit: Bayer AG. Bayer has announced a voluntary recall

November 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.